Chioma Ozioma S, Drake Wonder P
Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN.
Yale J Biol Med. 2017 Jun 23;90(2):219-227. eCollection 2017 Jun.
Pulmonary fibrosis is a form of lung disease that develops due to aberrant wound-healing following repeated alveoli injury in genetically susceptible individuals, resulting in chronic inflammation, excess deposition of the extracellular matrix components, mainly collagen, and scarring of lung tissue. In addition to irradiation, environmental agents such occupational inhalants, and chemotherapeutic agents, microbial agents also play a role in the etiology of the disease. While viruses have received the most attention, emerging evidence suggest that bacteria and fungi also play a part in the etiology of pulmonary fibrosis. Furthermore, successful use of antibiotics, antiviral and antifungal drugs in several studies to attenuate fibrosis progression is also an indication of microbial involvement in the pathogenesis of the disease and could be a promising therapeutic modality for treating pulmonary fibrosis initiated or exacerbated by infectious agents.
肺纤维化是一种肺部疾病,在基因易感性个体中,由于反复的肺泡损伤后异常的伤口愈合而发生,导致慢性炎症、细胞外基质成分(主要是胶原蛋白)过度沉积以及肺组织瘢痕形成。除了辐射、环境因素(如职业吸入物和化疗药物)外,微生物因素在该疾病的病因中也起作用。虽然病毒受到了最多关注,但新出现的证据表明细菌和真菌在肺纤维化的病因中也起作用。此外,在多项研究中成功使用抗生素、抗病毒和抗真菌药物来减轻纤维化进展,这也表明微生物参与了该疾病的发病机制,并且可能是治疗由感染因素引发或加重的肺纤维化的一种有前景的治疗方式。